1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Relapsed or Refractory Acute Lymphoblastic Leukemia: new trials by email Literature Review of Relapsed or Refractory Acute Lymphoblastic Leukemia trials Research Report on Relapsed or Refractory Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) ssCART-19, Fludarabine, Cyclophosphamide - Relapsed or Refractory Acute Lymphoblastic Leukemia | Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 50 | 2024-04-01 | 2024-04-19 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cyclophosphamide (1) · fludarabine (1)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1)
China (1)